Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.
More than one-third of patients with systemic lupus erythematosus experience a flare after starting dialysis for end-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback